The corpus

A practical comparison of Claude Opus 4.7, GPT-5, and Gemini 3 inside autonomous coding agents — tool-use reliability, long-horizon task completion, and per-task cost.

Practical breakdown of the three dominant developer-facing coding agents — workflow style, where each shines, and which to pick for refactors, greenfield work, or terminal-heavy projects.

Comparison of OpenAI text-embedding-3, Voyage AI voyage-3, Jina v3, and BAAI bge models — benchmark performance, dimensionality, and when local beats API.

Cost comparison across Gemini Flash, Claude Haiku, GPT-5 Nano, DeepSeek, and Groq-hosted open models — including caching, batch discounts, and where quality holds at scale.

pgvector, Pinecone, Weaviate, Qdrant, Chroma, and Milvus compared on operational footprint, latency at scale, hybrid search support, and total cost of ownership.

Overview of AI agents purpose-built for legal research and case-law analysis. Covers Harvey AI, Lex Machina, Casetext / CoCounsel, and the practical limits of general-purpose Claude / GPT for legal work.

Comparison of the dominant AI coding extensions for VS Code in 2026 — Cline, Continue, GitHub Copilot, and the new Cursor / Windsurf forks. Practical workflow notes, not a benchmark.

Comparison of 4K productivity monitors stocked at Swedish retailers in early 2026, focusing on warranty coverage, EU compliance, and price including moms (VAT).

Survey of cloud providers operating data centers in the EU under EU jurisdiction, with notes on Schrems II considerations, sovereign clouds, and pricing relative to AWS / GCP.

Comparison of Steuersoftware options that handle Einkommensteuererklärung + Umsatzsteuervoranmeldung for freelancers. Covers ELSTER integration, EÜR support, and pricing.

Practical comparison of EV fast-charging networks for cross-country US travel — coverage, reliability, pricing, and Tesla NACS adapter compatibility for non-Tesla EVs.

Survey of calendar + task tools that work well for ADHD-style scheduling — visual time blocking, frictionless capture, and explicit support for executive-function deficits. Covers Sunsama, Motion, Akiflow, Reclaim, Fantastical.

Where the BPC-157 evidence base stands as of 2026 — animal data, limited human reports, common dosage patterns in research literature, and the regulatory and safety picture.

How the GLP-1 class has evolved through 2026 — single-pathway agonists (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/glucagon (retatrutide). Efficacy, side effects, and where each currently fits.

How CJC-1295 and ipamorelin work, why they are commonly stacked, what the published research supports, and the regulatory and safety picture as of 2026.

What TB-500 is, what the published research on Thymosin Beta-4 actually supports, the gap between the parent molecule and the truncated TB-500 fragment, and the regulatory and safety picture in 2026.

Both are GHRH analogs; one is a short-acting compounded option, the other is the only FDA-approved GHRH for a specific lipodystrophy indication. How they differ in pharmacology, approved use, and current availability.

Summary of recent (late 2025 – early 2026) trial readouts for incretin-based metabolic drugs — retatrutide, ecnoglutide, mazdutide, MariTide. Efficacy, safety, and how they compare to semaglutide / tirzepatide.